Custom Pharma Services

Custom Pharma Services

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Custom Pharma Services is a private, revenue-generating CDMO focused on the contract manufacturing and packaging of small molecule, oral solid dose pharmaceuticals. The company leverages its MHRA-approved UK facility, technical expertise in process engineering, and regulatory savvy to serve clients from technology transfer through commercial launch. Its strategic differentiators include high operational dependability, a full-scope service model, and a partnership with Centrix Pharma Solutions for early-stage development, positioning it as a trusted partner for pharmaceutical companies in Europe.

Drug DeliverySmall Molecules

Technology Platform

Integrated oral solid dose (OSD) contract manufacturing platform specializing in tablets, capsules, caplets, and powders. Capabilities include immediate/modified release formulations, handling of controlled/hormonal drugs, and full-scope services from tech transfer to primary packaging in an MHRA-approved facility.

Opportunities

Growth in pharmaceutical outsourcing and demand for reliable, EU/UK-based CDMO services.
The partnership with Centrix Pharma Solutions creates an integrated offering from early development to commercial manufacturing, capturing clients earlier in the value chain.
Niche expertise in complex formulations (controlled drugs, hormones) offers higher-value opportunities.

Risk Factors

Intense competition in the CDMO market from larger global and regional players.
Operational and regulatory risk, where any failure in GMP compliance or quality control could severely damage reputation and business.
Dependence on the health of the biopharma sector and client R&D budgets, making it susceptible to industry downturns.

Competitive Landscape

Competes in the crowded global and European CDMO market for small molecule oral solid doses. Differentiators include UK/MHRA regulatory focus, niche capabilities with controlled substances, and a partnership for early-stage development. Faces competition from large multinational CDMOs (e.g., Catalent, Lonza) and other regional European specialists.